BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31787568)

  • 61. Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia.
    Desplanques PY; Burlacu R; Poinsignon V; Boussion H; Borget I; Wyplosz B; de Botton S; Billaud E; Chachaty E; Gachot B; Netzer F; Micol JB
    Med Mal Infect; 2014 Apr; 44(4):174-9. PubMed ID: 24656841
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes.
    Nganthavee V; Phutthasakda W; Atipas K; Tanpong S; Pungprasert T; Dhirachaikulpanich D; Krithin S; Tanglitanon S; Jutidamronphang W; Owattanapanich W; Chayakulkeeree M; Phikulsod P
    Support Care Cancer; 2019 Sep; 27(9):3613-3622. PubMed ID: 31165931
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
    Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Management of Invasive Fungal Infections in Pediatric Acute Leukemia and the Appropriate Time for Restarting Chemotherapy.
    Tüfekçi Ö; Yılmaz Bengoa Ş; Demir Yenigürbüz F; Şimşek E; Karapınar TH; İrken G; Ören H
    Turk J Haematol; 2015 Dec; 32(4):329-37. PubMed ID: 25913290
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
    Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
    Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: Clinical features, risk factors, and posaconazole profiles.
    Hong JY; Kang CI; Yang J; Ko JH; Huh K; Cho SY; Chung DR; Jung CW; Peck KR
    Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37120735
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia.
    Devanlay C; Tavernier-Tardy E; Bourmaud A; Falk AT; Raberin H; Menguy S; Guyotat D; Magné N; Cornillon J
    Biomed J; 2015; 38(3):235-43. PubMed ID: 25355388
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital.
    Chan TS; Marcella SW; Gill H; Hwang YY; Kwong YL
    J Med Econ; 2016; 19(1):77-83. PubMed ID: 26366612
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia.
    Chabrol A; Cuzin L; Huguet F; Alvarez M; Verdeil X; Linas MD; Cassaing S; Giron J; Tetu L; Attal M; Récher C
    Haematologica; 2010 Jun; 95(6):996-1003. PubMed ID: 20007135
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients.
    Maschmeyer G; Haas A; Cornely OA
    Drugs; 2007; 67(11):1567-601. PubMed ID: 17661528
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antifungal prophylaxis in liver transplant recipients: one size does not fit all.
    Giannella M; Bartoletti M; Morelli M; Cristini F; Tedeschi S; Campoli C; Tumietto F; Bertuzzo V; Ercolani G; Faenza S; Pinna AD; Lewis RE; Viale P
    Transpl Infect Dis; 2016 Aug; 18(4):538-44. PubMed ID: 27237076
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
    Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
    Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
    Rausch CR; DiPippo AJ; Jiang Y; DiNardo CD; Kadia T; Maiti A; Montalban-Bravo G; Ravandi F; Kontoyiannis DP
    Clin Infect Dis; 2022 Oct; 75(9):1503-1510. PubMed ID: 35325094
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study.
    Koehler P; Hamprecht A; Bader O; Bekeredjian-Ding I; Buchheidt D; Doelken G; Elias J; Haase G; Hahn-Ast C; Karthaus M; Kekulé A; Keller P; Kiehl M; Krause SW; Krämer C; Neumann S; Rohde H; La Rosée P; Ruhnke M; Schafhausen P; Schalk E; Schulz K; Schwartz S; Silling G; Staib P; Ullmann A; Vergoulidou M; Weber T; Cornely OA; Vehreschild MJ
    Int J Antimicrob Agents; 2017 Feb; 49(2):218-223. PubMed ID: 27989379
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].
    Lazzaro C
    Infez Med; 2010 Jun; 18(2):91-103. PubMed ID: 20610931
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Posaconazole and fluconazole prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia.
    Zhang T; Bai J; Huang M; Li R; Liu Y; Liu A; Liu J
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1139-1146. PubMed ID: 32828790
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia.
    Myoken Y; Sugata T; Kyo T; Fujihara M; Mikami Y
    J Periodontol; 2002 Jan; 73(1):33-8. PubMed ID: 11846198
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
    Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
    JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a large acute tertiary-care hospital.
    Abdul Salam ZH; Karlin RB; Ling ML; Yang KS
    Am J Infect Control; 2010 May; 38(4):e1-7. PubMed ID: 20129702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.